ライフサイエンスコーパス: after the end of

1 patients exhibited sustained virologic response at week 12 after the end of treatment.

2 The primary outcome was clinical cure 7 to 10 days after the end of treatment.

3 the level of HCV RNA below quantification at least 64 days after the end of treatment (beginning of week 12 after treatm

4 At 7 days after the end of randomised treatment, fewer patients had die

5 rth America and Mesoamerica, and in Eurasia, became evident after the end of the Neolithic period.

6 an additional MRS measurement in the left DLPFC immediately after the end of stimulation.

7 , into the PrL cortex prior to a BDNF infusion, immediately after the end of the last cocaine SA session, would block BDN

8 hly epistaxis duration for 3 consecutive months immediately after the end of the treatment.

9 epistaxis duration in the 3 consecutive months immediately after the end of treatment.

10 influencing the working synaptic range into adulthood, long after the end of the perinatal period.

11 aximal change in cardiac output should be assessed 1 minute after the end of the fluid infusion.

12 quality-of-life measures were significantly better 1 month after the end of chemotherapy in the scalp cooling group.

13 alf of the expected treatment has been reached and 6 months after the end of antiviral treatment.

14 6 months after the end of training, the incident rate of falls was als

15 outcome was the incident rate of falls during the 6 months after the end of training, which was assessed in a modified i

16 before treatment, 62% during (p = 0.016) and 28.6% 6 months after the end of treatment (p = 0.719).

17 se to 52.4% during treatment, and returned to 9.5% 6 months after the end of treatment, without significant difference be

18 d at 4 weeks, the end of treatment, and then 3 and 6 months after the end of treatment.

19 3 cycles of (223)RaCl2 (n = 52) and in 84% of the patients after the end of therapy (n = 32).

20 e during treatment, and no patients had a virologic relapse after the end of treatment.

21 us calcium (Ca(2+)) release (SCR) from intracellular stores after the end of a preceding action potential.

22 rs from April 2014 to January 2015 with a 6-month follow-up after the end of treatment.

23 ticipants achieving sustained virological response 12 weeks after the end of all study therapy (SVR12), defined as HCV RN

24 V RNA less than the lower limit of quantitation at 12 weeks after the end of all study therapy) in the per-protocol analy

25 ed virologic response (no detectable serum HCV RNA 12 weeks after the end of antiviral therapy).

26 tomography (PET-CT)-guided surveillance (performed 12 weeks after the end of chemoradiotherapy, with neck dissection perf

27 imary endpoint was sustained virologic response at 12 weeks after the end of therapy (SVR12).

28 logical response [SVR]12 (SVR of HCV RNA <15 IU/mL 12 weeks after the end of therapy).

29 file and high sustained virological response rates 12 weeks after the end of treatment (SVR12) in two phase 3 clinical tr

30 baseline RASs in NS5A on sustained viral response 12 weeks after the end of treatment (SVR12) with ledipasvir/sofosbuvir

31 on of patients with sustained virological response 12 weeks after the end of treatment (SVR12).

32 iremia (patients with sustained virologic response 12 weeks after the end of treatment but detectable HCV RNA at follow-u

33 The overall sustained virologic response rate 12 weeks after the end of treatment was 93.5% (186 of 199).

34 4 weeks' treatment, sustained virological response 12 weeks after the end of treatment was achieved in 6 patients (60%).

35 imary end point was a sustained virologic response 12 weeks after the end of treatment.

36 imary endpoint was sustained virologic response at 12 weeks after the end of treatment.

37 ble HCV RNA following sustained virologic response 12 weeks after the end of treatment.

38 mpleted 8 weeks of treatment and reached follow-up 12 weeks after the end of treatment.

39 t of 9 (89%) achieved sustained virologic response 12 weeks after the end of treatment.

40 The primary outcome was SVR at 12 weeks after the end of treatment.

41 treatment, at weeks 4 and 12 during treatment, and 24 weeks after the end of treatment.

42 lapsed, two achieved sustained virological response 4 weeks after the end of treatment but were lost to follow-up, and on

43 These results were observed nearly 1 year after the end of the project's facilitation of implementation

44 At week 78 (approximately 1 year after the end of the treatment phase), rates of opioid-negati

45 iority randomized clinical trial with a follow-up of 1 year after the end of treatment was conducted from July 15, 2011,

46 We also did an additional follow-up at 1 year after the end of treatment, as an interim analysis of the REP

47 (24.4) in HD14, and 30.7 (24.4) in HD15; in the fifth year after the end of treatment FA was 30.8 (26.0) in HD13, 27.1 (

48 Fatigue scores (FA) in the second year after the end of treatment were 28.5 (24.7) in HD13, 28.8 (24

49 ified control efforts totally vanished in only 2 to 3 years after the end of the program, calling for sustained political

50 15 patients with any valid fatigue assessment up to 5 years after the end of treatment.